Cargando…

P19-04. A synergistic effect of a combined bivalent DNA-protein anti-HIV-1 vaccine containing multiple T- and B-cell epitopes of HIV-1 proteins

Detalles Bibliográficos
Autores principales:	Ilyichev, A, Karpenko, L, Lebedev, L, Uzhachenko, R, Ilyicheva, T, Bazhan, S
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2767831/ http://dx.doi.org/10.1186/1742-4690-6-S3-P324

Ejemplares similares

P19-13. Recombinant proteins carrying peptide mimics of HIV-1
por: Chikaev, A, et al.
Publicado: (2009)

Design and Evaluation of Optimized Artificial HIV-1 Poly-T Cell-Epitope Immunogens
por: Reguzova, Alena, et al.
Publicado: (2015)

P04-43. Neutralizing antibody responses against conformational envelope epitopes in early HIV-1 infection
por: Bar, KJ, et al.
Publicado: (2009)

P16-04. Cryptic CTL epitopes derived from antisense transcription are frequently recognized in HIV-1 infection
por: Bansal, A, et al.
Publicado: (2009)

P05-02. Including peptides-mimotopes of neutralizing 2F5 epitope of HIV-1 into artificial peptide TBI – vaccine candidate
por: Scherbakova, NS, et al.
Publicado: (2009)

P04-20. Humoral immune response in acute HIV-1 infection
por: Mainetti, L, et al.
Publicado: (2009)

P12-04. Topology of the C-terminal tail of HIV-1 gp41: Differential exposure of the Kennedy epitope on cell and viral membranes
por: Steckbeck, JD, et al.
Publicado: (2009)

P04-33. Mechanisms of HIV-1 antibody mediated inhibition in Monomac-1 and MDM
por: Fischetti, L, et al.
Publicado: (2009)

Novel strategies for HIV-1 epitope delivery using foamy viral hybrid proteins and vectors
por: Mühle, M, et al.
Publicado: (2012)

The Structural and Immunological Properties of Chimeric Proteins Containing HIV-1 MPER Sites
por: Rudometov, A. P., et al.
Publicado: (2019)

P17-02. PolyCTLDesigner: the software for constructing highly efficient polyepitope immunogens. Application to HIV-1
por: Antonets, D, et al.
Publicado: (2009)

P04-52 LB. The importance of well-defined HIV-1 neutralization assays
por: Balla-Jhagjhoorsingh, SS, et al.
Publicado: (2009)

P10-04. Mechanisms of HIV-1 detection by plasmacytoid dendritic cells
por: Lepelley, A, et al.
Publicado: (2009)

Conservation of HIV-1 T cell epitopes across time and clades: validation of immunogenic HLA-A2 epitopes selected for the GAIA HIV vaccine
por: De Groot, AS, et al.
Publicado: (2012)

P04-46. Broadly cross-neutralizing activity in plasma of HIV-1 and HIV-2 infected individuals
por: Fenyö, E, et al.
Publicado: (2009)

P04-14. Sequential HIV-1 isolates from infected individuals reveals emergence of neutralization sensitive HIV-1 strains in the course of infection
por: Nyambi, PN, et al.
Publicado: (2009)

P04-48. HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after gp120 protein vaccination or chronic HIV-1 infection
por: Bonsignori, M, et al.
Publicado: (2009)

P17-04. Targeting HIV peptides to human dendritic cells via CD40 elicits expansion of multi-epitope polyfunctional CD4+ and CD8+ T cells in HIV patients
por: Flamar, A, et al.
Publicado: (2009)

Immunogenic selection of HIV-1 MPER epitopes for improved vaccine design
por: Wieczorek, L, et al.
Publicado: (2012)

P04-08. Monoclonal antibodies from patient with acute HIV-1 infection
por: Chen, W, et al.
Publicado: (2009)

P04-45. Characterization of the plasma cell repertoire in acute HIV-1 infection (AHI)
por: Liao, L, et al.
Publicado: (2009)

P04-04. The specific phospholipid binding and neutralizing activities of the anti-HIV antibody 4E10 are separable
por: Xu, H, et al.
Publicado: (2009)

P13-04. HIV positive women empowerment is equal to hiv prevalence reduction
por: Akolo, MM, et al.
Publicado: (2009)

Selection of Peptide Mimics of HIV-1 Epitope Recognized by Neutralizing Antibody VRC01
por: Chikaev, Anton N., et al.
Publicado: (2015)

P04-37. Kinetic and thermodynamic factors determine HIV-1 neutralizing potency of MPER-specific antibodies
por: Ruprecht, C, et al.
Publicado: (2009)

P04-40. Dissecting pre- and post-attachment activity of HIV-1 entry inhibitors and neutralizing antibodies
por: Berlinger, L, et al.
Publicado: (2009)

P19-36. Preclinical study of CombiHIVvac vaccine
por: Kaplina, O, et al.
Publicado: (2009)

P04-19. Analysis of the binding of multiple clades of HIV-1 by a modified virus capture assay
por: Peachman, K, et al.
Publicado: (2009)

P04-29. HIV-1 neutralizing antibodies inhibit plasmacytoid dendritic cells infection
por: Lederle, A, et al.
Publicado: (2009)

P07-04. HIV-1 evolution in mother to child transmission and pediatric disease progression
por: Dispinseri, S, et al.
Publicado: (2009)

P04-50 LB. Prevalence of cross-reactive HIV-1 neutralizing activity in HIV-1 infected patients with rapid or slow disease progression
por: van Gils, MJ, et al.
Publicado: (2009)

P04-44. Generation of antibody responses to HIV-1 membrane proximal external region (MPER) antigen
por: Holl, TM, et al.
Publicado: (2009)

P04-26. Immunological tolerance prevents the expression of a broadly reactive neutralizing HIV-1 antibody
por: Verkoczy, L, et al.
Publicado: (2009)

Alteration of HIV epitope processing and presentation by HIV protease inhibitors
por: Kourjian, G, et al.
Publicado: (2012)

P04-12. Characterization of leukopak PBMC phenotypes and biotypes for optimal performance in HIV-1 neutralization assays
por: Brown, BK, et al.
Publicado: (2009)

The interaction of HIV-1 and HIV-2 with cellular protein trafficking pathways
por: Alford, Justine, et al.
Publicado: (2013)

P01-04. Investigation of the sensitivity of acute-phase HIV-1 isolates to type I interferons
por: Dibben, O, et al.
Publicado: (2009)

Cross-group neutralization of HIV-1 and evidence for conservation of the PG9/PG16 epitopes within divergent groups of HIV-1
por: Braibant, M, et al.
Publicado: (2012)

P04-49 LB. Adaptation of HIV-1 envelope glycoprotein to humoral immunity at a population level
por: Bunnik, EM, et al.
Publicado: (2009)

P04-06. Evolution of an anti-MPER gp41 antibody response that mediates broad HIV-1 cross-neutralization
por: Gray, E, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_f77mq094jc5mdok3r7ruqab16a